We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

14 hedge funds and large institutions have $1.82M invested in ABVC BioPharma in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

0.18% more ownership

Funds ownership: 3.34% → 3.52% (+0.18%)

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

24% less capital invested

Capital invested by funds: $2.39M → $1.82M (-$566K)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $43K

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
8
Reduced
2
Closed
2
Calls
–
Puts
$43K
Net Calls
-$43K
Net Calls Change
-$43K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$107K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$54.9K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$39K
4
Jane Street
Jane Street
New York
+$29.1K
5
Northern Trust
Northern Trust
Illinois
+$19.5K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$59.6K
2
XT
XTX Topco
Cayman Islands
-$36.3K
3
Simplex Trading
Simplex Trading
Illinois
-$2.44K
4
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management
Wisconsin
-$456
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$613K +$54.9K +20,487 +8%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$431K +$39K +14,553 +8%
Renaissance Technologies
3
Renaissance Technologies
New York
$243K +$10.1K +3,763 +3%
State Street
4
State Street
Massachusetts
$155K – – –
BlackRock
5
BlackRock
New York
$120K – – –
Citadel Advisors
6
Citadel Advisors
Florida
$118K +$107K +39,879 +255%
Northern Trust
7
Northern Trust
Illinois
$68.3K +$19.5K +7,266 +29%
XT
8
XTX Topco
Cayman Islands
$24K -$36.3K -13,540 -55%
Jane Street
9
Jane Street
New York
$23.1K +$29.1K +10,867 New
Morgan Stanley
10
Morgan Stanley
New York
$11K +$13.9K +5,175 New
TRCT
11
Tower Research Capital (TRC)
New York
$6.8K +$2.78K +1,038 +48%
UBS Group
12
UBS Group
Switzerland
$5.51K +$1.98K +739 +40%
Simplex Trading
13
Simplex Trading
Illinois
$417 -$2.44K -912 -82%
Bank of America
14
Bank of America
North Carolina
$402 +$38 +14 +8%
Millennium Management
15
Millennium Management
New York
– -$59.6K -19,603 Closed
Northwestern Mutual Wealth Management
16
Northwestern Mutual Wealth Management
Wisconsin
– -$456 -150 Closed

ABVC Hedge Fund Activity: Q4 2025 in Review

14 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q4 2025, worth a combined $1.82M — down 24% from $2.39M a quarter earlier.

Fund positioning in ABVC was balanced in Q4 2025: 2 funds opened new positions, 2 closed out, 8 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $107K. The largest seller was Millennium Management, exiting entirely with an estimated $59.6K sold.

  • 14 institutional investors held ABVC BioPharma (ABVC) as of Q4 2025, unchanged from Q3 2025.
  • Funds reported $1.82M of ABVC BioPharma stock for Q4 2025, down 24% quarter-over-quarter.
  • 2 funds opened new ABVC BioPharma positions in Q4 2025 and 2 closed out, a net change of 0 holders.
  • The largest ABVC BioPharma buyer in Q4 2025 was Citadel Advisors, an estimated $107K added.
  • The largest ABVC BioPharma seller in Q4 2025 was Millennium Management, an estimated $59.6K sold.

Based on aggregated 13F filings for Q4 2025.